# OnCo record litespark-022 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/litespark-022/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "litespark-022", "NCT05239728" ;
  schema:name "LITESPARK-022"@en ;
  schema:description "Adding the HIF-2α pill to a year of adjuvant pembrolizumab further reduced recurrence, and became the first adjuvant combination approved in kidney cancer."@en ;
  schema:url <https://onco.cc/trials/litespark-022/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05239728>, <https://www.merck.com/news/merck-advances-treatment-of-bladder-and-kidney-cancers-with-new-data-at-2026-asco-gu-cancers-symposium/> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2022-03-15" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/hif2a/> ;
  onco:drugs <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> .